All In Biotech

Drug Trial Radar · NCT01077817

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women

Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

684,815

Actual

Start

Feb 26, 2010

Primary completion

Feb 16, 2012

Study completion Feb 16, 2012

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
Collaborators
World Health Information Science Consultants, LLC
First posted
Mar 1, 2010

More drug trials from this sponsor

Design

Study type
Observational
Who can join
Female only, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.

Conditions

  • Esophageal Cancer
  • Squamous Cell Carcinoma
  • Adenocarcinoma

Interventions

  • AlendronateDrug

  • EtidronateDrug

  • IbandronateDrug

  • RisedronateDrug

  • RaloxifeneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Exposure to Study Drugs (Case-Cohort Analysis)Time frame: Exposure to study drug at least 720 days before disease onset
  2. Number of Cases of Esophageal Cancer Per 100,000 Woman-Years (Intent-to-Treat Analysis)Time frame: Up to approximately 7.3 years of follow-up

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.